

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
*73*  
RLL-238US

In Re Application Of: **SALMAN et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/511,049		Unassigned	26815	unknown	

Title: **DERIVATIVES OF 2,2,4-TRISUBSTITUTED TETRAHYDROFURAN AS ANTIFUNGAL AGENTS**

Address to:  
**Commissioner for Patents**  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

**OR**

the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
**RLL-238US**

In Re Application: **SALMAN et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/511,049		Unassigned	26815	unknown	

Title: **DERIVATIVES OF 2,2,4-TRISUBSTITUTED TETRAHYDROFURAN AS ANTIFUNGAL AGENTS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of \_\_\_\_\_ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. **50-0912** as described below.
- Charge the amount of \_\_\_\_\_
- Credit any overpayment.
- Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as **first class** mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(e)] on

\_\_\_\_\_  
July 8, 2005

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Signature of Person Mailing Correspondence

\_\_\_\_\_  
Michelle Morgan

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

\_\_\_\_\_  
Signature

Dated: **July 8, 2005**

George E. Heibel, Esq.  
Reg. No. 42,648

CUSTOMER NO. 26815

CC:


**INFORMATION DISCLOSURE CITATION**

Docket No.: RLL-2-US

Serial No.: 10/511,049

Applicants: SALMAN et al.

Filed: 10/12/2004

Group:

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,992,421	2/12/1991	De et al.	514	19	
	A2	5,039,676	8/13/1991	Saksena et al.	514	254	
	A3	5,371,101	12/6/1994	Itoh et al.	514	383	
	A4	5,486,625	1/23/1996	Leong et al.	549	448	
	A5	5,661,151	8/26/1997	Saksena et al.	514	252	
	A6	5,703,236	12/30/1997	Saksena et al.	544	366	
	A7	6,034,248	3/7/2000	Itoh et al.	548	253	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO
	B1	WO 98/34934	8/13/1998	PCT	C07D	405/14	
	B2	EP 0 252 875	1/27/1993	EPO	A01N	46/653	
	B3	EP 0 296 518	12/28/1988	EPO	C07D	405/14	
	B4	EP 0 335 446	10/4/1989	EPO	C07D	405/06	
	B5	EP 0 443 980	8/28/1991	EPO	C07D	417/06	
	B6	EP 0 539 938	5/5/1993	EPO	C07D	405/06	
	B7	EP 0 555 186	8/11/1993	EPO	B27K	3/34	
	B8	JP 9-12574	1/14/1997	Japan	C07D	405/06	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

C1	Fromtling, "Overview of Medically Important Antifungal Azole Derivatives", <i>Clinical Microbiology Reviews</i> , 1(2):187-217 (1988)
C2	Greenspan, "Treatment of oropharyngeal candidiasis in HIV-positive patients", <i>The Journal of the American Academy of Dermatology</i> , 31:S51-S55 (1994)

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE CITATION

Docket No.: RLL-XXXXXXXXXX

Serial No.: 10/511,049

Applicants: SALMAN et al.

Filed: 10/12/2004

Group:

C3	Georgopapadakou and Walsh, "Antifungal Agents: Chemotherapeutic Targets and Immunologic Strategies", <i>Antimicrobial Agents and Chemotherapy</i> , <u>40</u> (2):279-291 (1996)
C4	Georgopapadakou, "Antifungals targeted to the cell wall", <i>Expert Opinion on Investigational Drugs</i> , <u>6</u> (2):147-150 (1997)
C5	Kauffman and Carver, "Antifungal Agents in the 1990s", <i>Drugs</i> , <u>53</u> (4):539-549 (1997)
C6	Koltin and Hitchcock, "The search for new triazole antifungal agents", <i>Current Opinion in Chemical Biology</i> , <u>1</u> :176-182 (1997)
C7	<u>Antifungal Agents</u> , "Principles and practice of infectious diseases", 4 <sup>th</sup> ed. pgs 401-410, G.L. Mandel, J.E. Bennett and R.Dolin (ed.), Churchill Livingstone, Inc. New York, N.Y
C8	Nguyen et al., "The Changing Face of Candidemia: Emergence of Non-Candida albicans Species and Antifungal Resistance", <i>The American Journal of Medicine</i> , <u>100</u> (6):617-623 (1996)
C9	Sheehan et al., "Current and Emerging Azole Antifungal Agents", <i>Clinical Microbiology Reviews</i> , <u>12</u> (1):40-79 (1999)
C10	Perfect et al., "In Vitro and In Vivo Efficacies of the Azole SCH56592 against <i>Cryptococcus neoformans</i> ", <i>Antimicrobial Agents and Chemotherapy</i> , <u>40</u> (8):1910-1913 (1996)
C11	36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1996, New Orleans. Abst. F74, F87-102
C12	Naito et al., "ER-34346 Triazole Antifungal", <i>Drugs of the Future</i> , <u>21</u> (1):20-24 (1996)
C13	Reimlinger et al., "Synthesen von s-Triazolo[3.4- $\alpha$ ]isochinolinen", <i>Chem. Ber.</i> , <u>103</u> :1960-1981 (1970)
C14	Reimlinger et al., "Weitere Oxidationen kondensierter Isochinoline, Synthese o-Carboxyphenyl-substituierter Heterocyclen", <i>Chem. Ber.</i> , <u>108</u> :3799-3806 (1975)
C15	Kitazaki et al., "Optically Active Antifungal Azoles. VI. <sup>1)</sup> Synthesis and Antifungal Activity of N-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-N'-(4-substituted phenyl)-3(2H,4H)-1,2,4-triazolones and 5(1H,4H)-tetrazolones", <i>Chemical and Pharmaceutical Bulletin</i> , <u>44</u> (2):314-327 (1996)
C16	Saag et al., "Azole Antifungal Agents: Emphasis on New Triazoles", <i>Antimicrobial Agents and Chemotherapy</i> , <u>32</u> (1):1-8 (1988)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.